US/UK/Canada

Share

Pick a time period -
Tags ( Active)

Oncopeptides will present at the BioStock Life Science Summit, November 20

The seventh edition of the BioStock Life Science Summit will take place in Lund on November 20-21. CEO Sofia Heigis will present Oncopeptides to industry leaders, specialist investors and potential partners. The Summit connects innovation and capital, providing small-to-medium size Nordic companies from a wide range of therapeutic areas the platform and opportunity to make their case to both Swedish and international investors as well as top-level potential partners in a unique boutique setting.    Date: November 20 Time: 13:00 Location: Auditorium at Medicon Village, Lund

Oncopeptides Chief Financial Officer Holger Lembrer takes office today

STOCKHOLM - January 18, 2023 - Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on commercialization, research, and development of therapies for difficult-to-treat hematological diseases, today announces that Holger Lembrer, who recently was appointed Chief Financial Officer, CFO, takes the office on January 18.“I am very pleased that Holger Lembrer assumes his position today, and really look forward to working together with him,” says Monica Shaw, CEO of Oncopeptides. “His combined expertise from leading financial roles, in a highly recognized, publicly traded,

Oncopeptides appoints Holger Lembrer as Chief Financial Officer

STOCKHOLM — January 11, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Company has appointed Holger Lembrer as Chief Financial Officer, CFO. Prior to joining Oncopeptides Holger Lembrer was Business Unit CFO at Assa Abloy, and before that Investor Relations Officer, and Financial Controller. He has also been a Senior Auditor at Ernst & Young. Holger Lembrer will assume his new position before the end of February 2023 and will replace Annika

Monica Shaw appointed CEO of Oncopeptides – Jakob Lindberg assumes position as Chief Scientific Officer

STOCKHOLM — January 4, 2023 — Oncopeptides AB (publ.) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Board of Directors has appointed Dr Monica Shaw as Chief Executive Officer, CEO, of Oncopeptides.  She replaces Jakob Lindberg, who has been the CEO since November 15, 2021. Lindberg assumes his previous position as Chief Scientific Officer.  These changes are effective immediately.The leadership changes follow a transformational year for Oncopeptides, when Pepaxti[®], was

Oncopeptides has announced the Nomination Committee

STOCKHOLM — December 22, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO). According to the principles for the appointment of the Nomination Committee in Oncopeptides AB (publ), the Nomination Committee for the annual general meeting 2023 shall be composed of members appointed by the three largest shareholders in terms of voting rights as of September 30 who are willing to participate in the Nomination Committee, along with the Chairman of the Board of Directors.The composition of the Nomination Committee has now been established, and Oncopeptides today announced that the Nomination

Oncopeptides presents new scientific data at the Annual American Society of Hematology Meeting ASH

STOCKHOLM — December 12, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the company presents new scientific data including one clinical abstract and three preclinical research posters at the Annual American Society of Hematology Meeting, ASH, in New Orleans, Louisiana, USA, on December 10-13. The clinical abstract evaluated patients with multiple myeloma who were refractory to prior alkylators in the phase 3 OCEAN study. Data shows that melflufen is a

Oncopeptides provides update on Pepaxto US marketing authorization

STOCKHOLM — December 07, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a global biotech company focused on the development of therapies for difficult-to-treat hematological diseases, today announces that the US Food and Drug Administration, FDA, has requested a withdrawal of the US marketing authorization for Pepaxto[® ](melphalan flufenamide, also called melflufen). The request is based on the outcome of the confirmatory phase 3 OCEAN study, which demonstrated an ITT overall survival HR of 1.1, but with significant survival result differences for both melflufen and the comparator

Oncopeptides enters into a renewed loan facility agreement of up to €30 million with the European Investment Bank

STOCKHOLM — November 25, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announced that the company has entered into a renewed unsecured loan facility agreement with the European Investment Bank (EIB), granting access to a conditional loan facility of up to €30 million.The loan facility agreement is divided into three tranches, each with a maturity of five years, which will become available if the company satisfies certain conditions precedent, including reaching

Oncopeptides’ Pepaxti has been granted marketing authorization in the UK

STOCKHOLM — November 11, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that Pepaxti[®] (melphalan flufenamide, also called melflufen) has been granted marketing authorization in combination with dexamethasone, by the Medicines & Healthcare products Regulatory Agency, MHRA, in UK.“The approval of Pepaxti in UK is one additional important milestone for Oncopeptides that further validates our science and data,” says Jakob Lindberg, CEO Oncopeptides AB. “

Oncopeptides publishes Q3 report 2022

STOCKHOLM — November 9, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publishes the report for the third quarter 2022.“The successful directed share issue in July and the approval of Pepaxti[®] in EU and EEA-countries in August, set the stage for a new and exciting phase for Oncopeptides,” says Jakob Lindberg, CEO of Oncopeptides. “With the ongoing launch in Germany we are entering a European market with potential revenue of approximately 1.5-2.0 billion SEK,

Oncopeptides announces the market potential for Pepaxti in Europe

STOCKHOLM — November 9, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces the estimated market potential for Pepaxti[®] in Europe. The potential assumes that the Company´s pending type 2 variation submission to the European Medicines Agency based on OCEAN data, will be approved by the agency, and enable patients with relapsed refractory multiple myeloma access to the drug in an earlier treatment line. Furthermore, the market potential assumes that price

Number of shares and votes in Oncopeptides

STOCKHOLM — October 31, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the number of shares and votes in Oncopeptides has changed as a result of the company’s issue of 3,940,607 new class C shares in accordance with the shareholder program Board SHP 2022 and the incentive program Co-worker LTIP 2022 adopted by the annual general meeting on June 28, 2022. Before the share issue, the total number of outstanding shares and votes in Oncopeptides amounted

Oncopeptides phase 3 LIGHTHOUSE study further confirms clinical benefit of melflufen

STOCKHOLM — October 26, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces data from the phase 3 LIGHTHOUSE study that further confirms the clinical benefit of melflufen in patients with relapsed refractory multiple myeloma (RRMM). The LIGHTHOUSE study investigated the efficacy and safety of the combination of melflufen plus daratumumab subcutaneous (sc) plus dexamethasone in comparison with daratumumab sc. (with supportive dexamethasone) in patients who were

Issue and re-purchase of class C shares for shareholder program and incentive program

STOCKHOLM — October 20, 2022 — The Board of Directors of Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO) (“Oncopeptides”), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, has today resolved, by virtue of the authorization by the Annual General Meeting held on June 28, 2022, to issue and immediately thereafter re-purchase a total of 3,940,607 class C shares. The shares are issued and re-purchased in accordance with the shareholder program and the incentive program which were adopted by the Annual General Meeting held on June 28,

Oncopeptides starts commercialization of Pepaxti in Europe – Germany first market

STOCKHOLM — October 3, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Company has submitted the AMNOG dossier to “The Federal Joint Committee” (G-BA) in Germany. This initiates the commercial launch of Pepaxti[®] (melphalan flufenamide) and thus Germany will be the first market in Europe where the drug is launched.On August 18, the European Commission granted Pepaxti, in combination with dexamethasone, Marketing Authorization in the European

Bulletin from an Extra Ordinary General meeting in Oncopeptides AB (publ)

Stockholm, Sweden – An Extraordinary General Meeting in Oncopeptides AB (publ) (ONCO) was held on Friday, 23 September 2022. At the Extraordinary General Meeting, the following principal resolution was passed.· It was resolved, in accordance with the Board of Directors’ proposal, to authorize the Board of Directors to, until the next Annual General Meeting, on one or more occasions, decide upon issuances of new shares. New issues of shares may occur with or without preferential rights for shareholders of the company and may be made either in cash and/or by way of set-off or contribution in

Oncopeptides provides an update from the meeting with FDAs advisory committee ODAC

STOCKHOLM — September 23, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the Oncologic Drugs Advisory Committee (ODAC), of the US Food and Drug Administration (FDA), has finalized the discussion on the benefit-risk profile of Pepaxto[®] (melphalan flufenamide, also called melflufen). A majority of the panel considered that OCEAN did not confirm a favorable benefit-risk profile in the current indicated patient population. Pepaxto is indicated in

Briefing Book for ODAC meeting on benefit/risk profile of Pepaxto now published

STOCKHOLM — September 20, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the US Food and Drug Administration (FDA), has published the Briefing Book for the Oncologic Drugs Advisory Committee (ODAC) meeting on September 22, 2022. The purpose of the meeting is to obtain the advisory committee´s input regarding the benefit/risk of Pepaxto[®] (melphalan flufenamide, also called melflufen) for the currently indicated patient population.“We have

Oncopeptides receives 5 MSEK grant for NK-cell engager project in multiple myeloma

STOCKHOLM — September 7, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the company has received a research grant of 5 MSEK from Sweden´s Innovation Agency, to develop preclinical proof of concept (PoC) for a novel synthetic small polypeptide for the treatment of multiple myeloma. The compound is a Natural Killer (NK) cell engaging immunotherapy, with superior tissue penetration and immune cell activation. The NK ENGAGE project has been qualified as a

Extraordinary General Meeting in Oncopeptides AB (publ)

The shareholders in Oncopeptides AB (publ), reg. no. 556596-6438, with registered office in the municipality of Stockholm, (“Oncopeptides” or the “Company”) are hereby given notice to attend the Extraordinary General Meeting to be held on Friday 23 September 2022.The Extraordinary General Meeting will be carried out through advance voting (postal voting) pursuant to temporary legislation. No meeting with the possibility to attend in person or to be represented by a proxy will take place. Hence, the General Meeting will be held without physical presence. Oncopeptides welcomes all

European Commission approves Oncopeptides' Pepaxti for the treatment of patients with relapsed refractory multiple myeloma

STOCKHOLM — August 18, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the European Commission has granted Pepaxti[®] (melphalan flufenamide, also called melflufen) marketing authorization  in combination with dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least three prior lines of therapies, whose disease is refractory to at least one proteasome inhibitor, one immunomodulatory agent, and one anti-CD38

Oncopeptides publishes Q2 report 2022

STOCKHOLM — August 11, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today publishes the report for the second quarter 2022.“CHMPs recommendation to grant Pepaxti a full marketing authorization approval in EU is foundational for Oncopeptides says Jakob Lindberg, CEO of Oncopeptides. “This is excellent news for patients, shareholders, and for the future development of Oncopeptides.” Financial overview April-June · Net sales amounted to SEK 8.8 M (66.4) ·

Number of shares and votes in Oncopeptides

Stockholm, Sweden — July 29, 2022 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on research and development of therapies for difficult-to-treat hematological diseases, today announces that the number of shares and votes in Oncopeptides has changed as a result of the company’s share issue as announced on July 14, 2022. As a result of the share issue, the number of outstanding shares and votes has increased by 15,061,443 from 75,307,217 to 90,368,660. The share capital has increased by approximately SEK 1,673,494 from SEK 8,367,469 to SEK 10,040,963.For further

There are no items matching the current filter
There are no more items matching the current filter
Back to top

Subscribe

Media